[Controlled clinical study of the effects of Anasclerol in hospitalized patients with cerebrovascular disorders].
A double-blind clinical trial of vincamine hydrochloride and a known dihydrogenated ergotoxine derivative, administered i.m. for 10 days, was conducted on 2 groups of 10 hospitalised cerebrovascular patients. Hemiplegia was evaluated prior to treatment and on its 5th and 10th day, by a scoring system. Statistical assessment of the results and the clinical observations showed that vincamine hydrochloride can be usefully employed in the treatment of acute cerebrovascular accidents on account of its marked effectiveness and rapid action--these being attributable to its cerebral vasoregulatory and metabolic mechanism, and to increased availability due to salification of the basic molecule--, coupled with its excellent local and general tolerability.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004873:Ergolines / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D014749:Vincamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D004873:Ergolines; D014748:Vinca Alkaloids; D014749:Vincamine
Studio clinico controllato sugli effetti dell'Anasclerol in pazienti cerebro-vasculopatici ospedalizzati.